Stock Price Quote

KILITCH DRUGS (INDIA) LTD.

NSE : KILITCHBSE : 524500ISIN CODE : INE729D01010Industry : Pharmaceuticals & DrugsHouse : Private
BSE250.001.35 (+0.54 %)
PREV CLOSE ( ) 248.65
OPEN PRICE ( ) 250.00
BID PRICE (QTY) 250.50 (200)
OFFER PRICE (QTY) 249.50 (200)
VOLUME 50
TODAY'S LOW / HIGH ( )250.00 250.00
52 WK LOW / HIGH ( )121.3 248.65
NSE249.150 (0 %)
PREV CLOSE( ) 249.15
OPEN PRICE ( ) 249.15
BID PRICE (QTY) 249.15 (1731)
OFFER PRICE (QTY) 249.00 (808)
VOLUME 5514
TODAY'S LOW / HIGH( ) 249.15 249.15
52 WK LOW / HIGH ( )125 249.15
BSE NSE
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1992
Management Info
- Chairman Mukund P Mehta - Managing Director
Registered Office

Address C 301/2 M I D C,T T C Industrial Area,Pawane Village,
Navi Mumbai,
Maharashtra-400705

Phone 022-62996300

Email info@kilitch.com

Website www.kilitch.com

Registrars Details
Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE, MCX

NEWS

24Jul Allotment of Convertible warrants
Inter alia, approved:- 1.Obtaining credit facilities from bank not exce..
24Jul Allotment of Equity Shares
Inter alia, approved:- 1.Obtaining credit facilities from bank not exce..
22Jul Kilitch Drugs (India) informs about ou
Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, Kilitch Drug..
19Jul Allotment of Convertible warrants
Inter alia, to consider and approve conversion of warrants into the equi..
19Jul Allotment of Equity Shares
Inter alia, to consider and approve conversion of warrants into the equi..
MORE

Financials

in Millions
QTR Jun 23 ANNUAL 23
Net Profit41.88157.18
Gross Profit 55.81 194.49
Operating Profit 62.17217.71
Net Sales 311.251177.84
MORE

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Dr. Reddy's Lab (BSE)
peergroup  5511.65 (1.33%)
M.Cap ( in Cr)91805.01
Guj. Themis Biosyn (BSE)
peergroup  919.40 (3.93%)
M.Cap ( in Cr)1332.21
Pfizer (BSE)
peergroup  3866.65 (0.80%)
M.Cap ( in Cr)17554.32
Natco Pharma (BSE)
peergroup  875.35 (3.13%)
M.Cap ( in Cr)15591.51
NGL Fine-Chem (BSE)
peergroup  2014.05 (1.08%)
M.Cap ( in Cr)1244.28
MORE

Shareholding Pattern

PROMOTERS 68.25%
NON-INSTITUTION 31.75%
FI/BANKS/INSURANCE 0%
MUTUAL FUNDS/UTI 0%
GOVERNMENT 0%
FII 0%
MORE

About Kilitch Drugs (India) Ltd.

Kilitch Drugs (India) Ltd. was incorporated in the year 1992. Its today's share price is 250. Its current market capitalisation stands at Rs 400.69 Cr. In the latest quarter, company has reported Gross Sales of Rs. 1051.6 Cr and Total Income of Rs.1097.19 Cr. The company's management includes Pushpa Nyoupane, Venkita Subramanian Rajan, Vasudev Krishna Murti, Hemang Engineer, Mira Mehta, Bhavin Mehta, Mukund P Mehta.

It is listed on the BSE with a BSE Code of 524500 , NSE with an NSE Symbol of KILITCH and ISIN of INE729D01010. It's Registered office is at C 301/2 M I D C,T T C Industrial Area,Pawane VillageNavi Mumbai-400705, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are AM Ghelani & Co, RNR Iyer & Co, Suryaprakash Maurya & Co

download beyond app
download beyond app
About Nirmal Bang About Nirmal Bang Awards & Accolades Careers at Nirmal Bang Contact Nirmal BangContact Dp Support Contact Trading Support
Product & Services Equity & Derivatives Trading Forex Trading Commodity Trading Institutional Broking Depository Services Loan Against Securities (LAS) Algo Trading
Equity Price Analysis Volume Analysis Index Analysis News Analysis Corporate Action India Market Other Market Share Market Holidays T+1 Settlement securities
Derivatives Updates Market Report Overview
IPO IPO Issues Performance News & Analysis
Commodities Market Movers News & Commentary MCX / NCDEX HolidaysMCX Data feed product and Charges
Portfolio Management Service (PMS) NBSPL - PMS Disclosure Nirmal Bang PMS - Investor Charter
Mutual Funds About Nirmal Bang Niveshalaya Why Associate with Nirmal Bang Mutual Fund Login Mutual Fund Register FAQs Mutual Fund Holidays SIP Calculator Mutual Funds Updates Mutual Funds Trends Mutual Fund Reports Mutual Fund Terms & Conditions Mutual Privacy Policy
Nirmal Bang Research Technical Calls Equity Reports Commodity Reports Currency Research Institutional Research
Nirmal Bang Media Knowledge Center Blog Support Center Become A Partner Beyond Market Careers Sitemap Do's And Dont'sInvestor Complaint Data
Other Links Disclaimer Privacy Policy Terms Of Use Rules & Regulations Disclosures Risk Disclosure Grievances NPS Grievance Policy SEBI ScoresRMS Policy Inspection CSR Committee CSR Policy
CSR Activities
FY-2020-2021 FY-2021-2022 FY-2022-2023
Investor Charter
Linked content_Investor Charter for Depositories and DPs Investor Charter for Depositories and DPs Investor Charter for Stock Broker Investor Charter for Research Investor Complaints -RA Investor Complaints-NBEPL
Evoting
NSDL Evoting CDSL Evoting
Client Bank Account list Smartodr Login Investor Grievance Flow Registered AP’sSurrendered List of AP’sKYC Activation Process
Connect with Us
ATTENTION INVESTORS Depository IPO KYC
Inactive account treatmentNBSPL Policy of AMLNBEPL Policy of AMLNBSPL CSR Policy Physical Settlement Policy of Derivative Aadhar UpdationNirmalbang Privacy Policy V1.0 Documents in Vernacular Languages NBSPL PMS Disclosure Document
Nirmal Bang Securities Pvt. Ltd. : Member NSE – ID 09391, SEBI Registration No. NSE CM Segment INZ000202536, Member NSE – ID 09391, SEBI Registration No. NSE FO Segment INZ000202536, Member NSE – ID 09391, SEBI Registration No. NSE CDS Segment INZ000202536, Member NSE Commodity – ID 09391, SEBI Registration No. NSE COMMODITY Segment Exchange Registered Broker, Member MSEI – ID 1067, SEBI Registration No. MSEI CM Segment INZ000202536, Member MSEI – ID 1067, SEBI Registration No. MSEI FO Segment INZ000202536, Member MSEI – ID 1067, SEBI Registration No. MSEI CDS Segment INZ000202536, Member MCX – ID 56460, SEBI Registration No. MCX COMMODITY Segment INZ000202536, Member NCDEX – ID 1268, SEBI Registration No. NCDEX COMMODITY Segment INZ000202536, Member ICEX – ID 2073, SEBI Registration No. ICEX COMMODITY Segment INZ000202536, Member BSE – ID 0498, SEBI Registration No. BSE CM Segment INZ000202536, Member BSE – ID 0498, SEBI Registration No. BSE FO Segment INZ000202536, Member BSE – ID 0498, SEBI Registration No. BSE CDS Segment Exchange Registered Broker, Member BSE Commodity – ID 0498, SEBI Registration No. BSE COMMODITY Segment Exchange Registered Broker, SEBI Registration No. PMS INP000002981, SEBI Registration No. Research Analyst INP000002981, SEBI Registration No. DP Participants NSDL – CDSL IN-DP-CDSL 37-99,Member Comtrack Participant Id – ID 50274, Member NERL RP Id– ID R1447, Nirmal Bang Equities Private Limited Member BSE – ID 245, SEBI Registration No. BSE CM Segment INZ000186135, Member NSE – ID 13437, SEBI Registration No. BSE CM Segment INZ000186135, Member NSE – ID 13437, SEBI Registration No. NSE FO Segment INZ000186135, Member NSE Currency – ID 13437, SEBI Registration No. NSE CDS Segment INZ000186135, Member MSEI – ID 17780, SEBI Registration No. MSEI CM Segment INZ000186135, Member MSEI – ID 17780, SEBI Registration No. MSEI FO Segment INZ000186135, SEBI Registration No. Research Analyst Segment INH000001436, Nirmal Bang Commodities Private Limited Member MCX – ID 16590, SEBI Registration No. MCX COMMODITY Segment INZ000043630, Member NCDEX – ID 00362, SEBI Registration No. NCDEX COMMODITY Segment INZ000043630, Member ICEX – ID 1165, SEBI Registration No. ICEX COMMODITY Segment INZ000043630, Member NCDEX Spot Exchange – ID 10084,Comtrack Participant CPID -5040, Participant CDSL Commodity Repository Limited - 12013300
For any grievances, please get in touch on 022-62739390 and write a mail to Contact@nirmalbang.com with Subject line as Grievances/Complain.     |    

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by ●●● Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

AppleApp Store GooglePlay Store
AppleApp StoreGooglePlay Store
Support
Videos
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.